GOLM1 promotes prostate cancer progression via interaction with PSMD1 and enhancing AR‐driven transcriptional activation

• Published in: Journal of cellular and molecular medicine Vol. 28; no. 20; pp. e70186 - n/a
• Main Authors: Yan, Guang, Zhu, Tianhang, Zhou, Jiawei, Li, Xia, Wen, Zonghua, Miuhuitijiang, Bahaerguli, Zhang, Zhiyong, Du, Yuejun, Li, Chengyao, Shi, Xiaojun, Tan, Wanlong
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01-10-2024; John Wiley and Sons Inc
• Subjects: Androgen receptors; Androgens; Animals; Antibodies; Cell growth; Cell Line, Tumor; Correlation analysis; Disease Progression; Enzymes; Gene Expression Regulation, Neoplastic; Gene regulation; Golgi apparatus; GOLM1; Humans; Immunohistochemistry; Laboratories; Liver cancer; Lung cancer; Male; Mass spectrometry; Mass spectroscopy; Medical research; Membrane Proteins - genetics; Membrane Proteins - metabolism; Mice; Original; Prostate cancer; Prostatic Neoplasms - genetics; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - pathology; Proteasome 26S; Proteasome Endopeptidase Complex - metabolism; Proteasomes; Protein Binding; Proteins; PSMD1; Receptors, Androgen - genetics; Receptors, Androgen - metabolism; Scientific imaging; Survival analysis; Therapeutic targets; Transcription activation; Transcriptional Activation - genetics; Ubiquitin; UPS; England; United Kingdom > UK; United States > US; Texas; China; AR; PSMD1; UPS; prostate cancer; GOLM1
• ISSN: 1582-1838; 1582-4934; 1582-4934
• DOI: 10.1111/jcmm.70186

Aberrant transcriptional activation of the androgen receptor (AR) is a predominant cause of prostate cancer (PCa), including both in the initial and androgen‐independent stages. Our study highlights Golgi membrane protein 1 (GOLM1) as a key regulator of AR‐driven transcriptional activity in PCa progression. Utilizing local clinical data and TCGA data, we have established a robust association between GOLM1 and AR target genes, and further demonstrated that GOLM1 can enhance the expression of AR target genes. We discovered that GOLM1 interacts with PSMD1, a component of the 19S regulatory complex in the 26S proteasome, using mass spectrometry and Co‐IP analysis. It is well known that ubiquitin‐proteasome plays a vital role in AR expression and transcriptional regulation. Our findings demonstrate that GOLM1 enhances ubiquitin proteasome activity by binding to PSMD1, thereby facilitating AR‐driven transcriptional activity and PCa progression. These results indicate that GOLM1 and its associated proteins may become potential therapeutic targets for PCa characterized by dysregulated AR‐driven transcriptional activation.